Literature DB >> 22101894

Induction of acute GVHD by sex-mismatched H-Y antigens in the absence of functional radiosensitive host hematopoietic-derived antigen-presenting cells.

Tomomi Toubai1, Isao Tawara, Yaping Sun, Chen Liu, Evelyn Nieves, Rebecca Evers, Thea Friedman, Robert Korngold, Pavan Reddy.   

Abstract

It is currently thought that acute GVHD cannot be elicited in the absence of Ag presentation by radiosensitive host hematopoietic-derived APCs after allogeneic BM transplantation. Because clinical data suggest that sex-mismatched H-Y Ags may be important minor histocompatibility Ags for GVH responses, we directly tested their relevance and ability to initiate GVHD when presented by either the hematopoietic- (host or donor) or the nonhematopoietic-derived APCs. H-Y minor Ag incompatibility elicited both CD4(+) and CD8(+) T-cell driven GVHD lethality. Studies with various well-established BM chimera recipients, in contrast to the current views, have reported that in the absence of functional radiosensitive host hematopoietic-derived APCs, H-Y Ag presentation by either the donor hematopoietic-derived or the host nonhematopoietic-derived APCs is sufficient for inducing GVHD. Our data further suggest that infusion of sufficient numbers of alloreactive donor T cells will induce GVHD in the absence of radiosensitive host hematopoietic-derived APCs.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22101894      PMCID: PMC3335388          DOI: 10.1182/blood-2011-10-384057

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  45 in total

1.  Host MHC class II+ antigen-presenting cells and CD4 cells are required for CD8-mediated graft-versus-leukemia responses following delayed donor leukocyte infusions.

Authors:  Ronjon Chakraverty; Hyeon-Seok Eom; Jessica Sachs; Jennifer Buchli; Pete Cotter; Richard Hsu; Guiling Zhao; Megan Sykes
Journal:  Blood       Date:  2006-06-06       Impact factor: 22.113

2.  Isolation of mouse small intestinal intraepithelial lymphocytes, Peyer's patch, and lamina propria cells.

Authors:  L Lefrançois; N Lycke
Journal:  Curr Protoc Immunol       Date:  2001-05

3.  The fate of donor T-cell receptor transgenic T cells with known host antigen specificity in a graft-versus-host disease model.

Authors:  B Dey; Y G Yang; F Preffer; A Shimizu; K Swenson; D Dombkowski; M Sykes
Journal:  Transplantation       Date:  1999-07-15       Impact factor: 4.939

4.  Prevention of graft versus host disease by inactivation of host antigen-presenting cells.

Authors:  W D Shlomchik; M S Couzens; C B Tang; J McNiff; M E Robert; J Liu; M J Shlomchik; S G Emerson
Journal:  Science       Date:  1999-07-16       Impact factor: 47.728

5.  T cells targeted against a single minor histocompatibility antigen can cure solid tumors.

Authors:  Marie-Christine Meunier; Jean-Sébastien Delisle; Julie Bergeron; Vincent Rineau; Chantal Baron; Claude Perreault
Journal:  Nat Med       Date:  2005-10-16       Impact factor: 53.440

6.  A crucial role for antigen-presenting cells and alloantigen expression in graft-versus-leukemia responses.

Authors:  Pavan Reddy; Yoshinobu Maeda; Chen Liu; Oleg I Krijanovski; Robert Korngold; James L M Ferrara
Journal:  Nat Med       Date:  2005-10-16       Impact factor: 53.440

7.  T-cell receptor Valpha spectratype analysis of a CD4-mediated T-cell response against minor histocompatibility antigens involved in severe graft-versus-host disease.

Authors:  Christine G DiRienzo; George F Murphy; Stephen C Jones; Robert Korngold; Thea M Friedman
Journal:  Biol Blood Marrow Transplant       Date:  2006-08       Impact factor: 5.742

8.  Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice.

Authors:  Pavan Reddy; Yaping Sun; Tomomi Toubai; Raimon Duran-Struuck; Shawn G Clouthier; Elizabeth Weisiger; Yoshinobu Maeda; Isao Tawara; Oleg Krijanovski; Erin Gatza; Chen Liu; Chelsea Malter; Paolo Mascagni; Charles A Dinarello; James L M Ferrara
Journal:  J Clin Invest       Date:  2008-07       Impact factor: 14.808

9.  Inducing the tryptophan catabolic pathway, indoleamine 2,3-dioxygenase (IDO), for suppression of graft-versus-host disease (GVHD) lethality.

Authors:  Lisa K Jasperson; Christoph Bucher; Angela Panoskaltsis-Mortari; Andrew L Mellor; David H Munn; Bruce R Blazar
Journal:  Blood       Date:  2009-10-14       Impact factor: 22.113

10.  Alloantigen affinity and CD4 help determine severity of graft-versus-host disease mediated by CD8 donor T cells.

Authors:  Xue-Zhong Yu; Michael H Albert; Claudio Anasetti
Journal:  J Immunol       Date:  2006-03-15       Impact factor: 5.422

View more
  38 in total

Review 1.  Immunopathology and biology-based treatment of steroid-refractory graft-versus-host disease.

Authors:  Tomomi Toubai; John Magenau
Journal:  Blood       Date:  2020-07-23       Impact factor: 22.113

2.  Investigating the Association of Genetic Admixture and Donor/Recipient Genetic Disparity with Transplant Outcomes.

Authors:  Abeer Madbouly; Tao Wang; Michael Haagenson; Vanja Paunic; Cynthia Vierra-Green; Katharina Fleischhauer; Katharine C Hsu; Michael R Verneris; Navneet S Majhail; Stephanie J Lee; Stephen R Spellman; Martin Maiers
Journal:  Biol Blood Marrow Transplant       Date:  2017-03-02       Impact factor: 5.742

3.  T cells take directions from supporting cast in graft-versus-host disease.

Authors:  Derk Amsen
Journal:  J Clin Invest       Date:  2017-03-20       Impact factor: 14.808

4.  Fibroblastic niches prime T cell alloimmunity through Delta-like Notch ligands.

Authors:  Jooho Chung; Christen L Ebens; Eric Perkey; Vedran Radojcic; Ute Koch; Leonardo Scarpellino; Alexander Tong; Frederick Allen; Sherri Wood; Jiane Feng; Ann Friedman; David Granadier; Ivy T Tran; Qian Chai; Lucas Onder; Minhong Yan; Pavan Reddy; Bruce R Blazar; Alex Y Huang; Todd V Brennan; D Keith Bishop; Burkhard Ludewig; Christian W Siebel; Freddy Radtke; Sanjiv A Luther; Ivan Maillard
Journal:  J Clin Invest       Date:  2017-03-20       Impact factor: 14.808

Review 5.  Biology of graft-versus-host responses: recent insights.

Authors:  Kelli P MacDonald; Warren D Shlomchik; Pavan Reddy
Journal:  Biol Blood Marrow Transplant       Date:  2013-01       Impact factor: 5.742

6.  Cellular therapy of the host to prevent GVHD.

Authors:  James Ferrara
Journal:  Blood       Date:  2014-09-11       Impact factor: 22.113

7.  Siglec-G represses DAMP-mediated effects on T cells.

Authors:  Tomomi Toubai; Corinne Rossi; Katherine Oravecz-Wilson; Cynthia Zajac; Chen Liu; Thomas Braun; Hideaki Fujiwara; Julia Wu; Yaping Sun; Stuart Brabbs; Hiroya Tamaki; John Magenau; Pang Zheng; Yang Liu; Pavan Reddy
Journal:  JCI Insight       Date:  2017-07-20

8.  MHC Class II Antigen Presentation by the Intestinal Epithelium Initiates Graft-versus-Host Disease and Is Influenced by the Microbiota.

Authors:  Motoko Koyama; Pamela Mukhopadhyay; Iona S Schuster; Andrea S Henden; Jan Hülsdünker; Antiopi Varelias; Marie Vetizou; Rachel D Kuns; Renee J Robb; Ping Zhang; Bruce R Blazar; Ranjeny Thomas; Jakob Begun; Nicola Waddell; Giorgio Trinchieri; Robert Zeiser; Andrew D Clouston; Mariapia A Degli-Esposti; Geoffrey R Hill
Journal:  Immunity       Date:  2019-09-18       Impact factor: 31.745

9.  Host-derived CD8+ dendritic cells are required for induction of optimal graft-versus-tumor responses after experimental allogeneic bone marrow transplantation.

Authors:  Tomomi Toubai; Yaping Sun; Gary Luker; Jun Liu; Kathryn E Luker; Isao Tawara; Rebecca Evers; Chen Liu; Nathan Mathewson; Chelsea Malter; Evelyn Nieves; Sung Choi; Kenneth M Murphy; Pavan Reddy
Journal:  Blood       Date:  2013-03-21       Impact factor: 22.113

10.  Allogeneic Th1 cells home to host bone marrow and spleen and mediate IFNγ-dependent aplasia.

Authors:  Joseph H Chewning; Weiwei Zhang; David A Randolph; C Scott Swindle; Trenton R Schoeb; Casey T Weaver
Journal:  Biol Blood Marrow Transplant       Date:  2013-03-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.